Showing 7811-7820 of 9807 results for "".
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Eye on the AD Pipeline: Dermavant Completes Enrollment of Phase 3 Trials of VTAMA in Adults and Children with ADhttps://practicaldermatology.com/news/eye-on-the-ad-pipeline-dermavant-completes-enrollment-of-phase-3-trials-of-vtama-in-adults-and-children-with-ad/2461561/Dermavant Sciences has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old. VTAMA cream is a novel, aryl hydrocarbon receptor agonist
- Povorcitinib Produces Lasting Results in HShttps://practicaldermatology.com/news/povorcitinib-produces-lasting-results-in-hs/2461557/Longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms in a phase 2 study of hidradenitis suppurativa (HS) patients. Povorcitinib is an oral JAK1 inhibitor. These data were presented as an oral presentation at th
- LEO Pharma Announces Positive Phase 3 Trial Results for Delgocitinib Cream in Adults With Chronic Hand Eczema (CHE)https://practicaldermatology.com/news/leo-pharma-announces-positive-phase-3-trial-results-for-delgocitinib-cream-in-adults-with-chronic-hand-eczema-che/2461556/LEO Pharma announced positive results of the DELTA 2 trial, the second of two pivotal phase 3 clinical trials evaluating delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- Cutera Launches Rewards Program for High-Volume AviClear Usershttps://practicaldermatology.com/news/cutera-launches-rewards-program-for-high-volume-aviclear-users/2461548/Practices in the United States and Canada using AviClear will now have access to more perks. Cutera announced that it will be launching a rewards program for AviClear practices designed to reinforce a partnership approach with practices with improved profitability, e
- NRS Announces 2023 Rosacea Awareness Month Theme: Give New Treatments Time to Workhttps://practicaldermatology.com/news/nrs-announces-2023-rosacea-awareness-month-theme-give-new-treatments-enough-time-to-work/2461547/This Rosacea Awareness Month, the National Rosacea Society (NRS) is highlighting the importance of consistency and patience when trying new therapies. “Rosacea has no cure, but the signs and symptoms can go into remission through a combination of medical therapy and life
- New Biomarkers May Help Advance Melanoma Detectionhttps://practicaldermatology.com/news/new-biomarkers-may-help-advance-melanoma-detection/2461539/New biomarkers to improve skin cancer detection and avoid delays in treatment are being developed by researchers at the University of South Australia. “Melanomas exhibit a wide range of sizes, shapes and growth, which can resemble numerous benign and other malignant skin lesions,&
- Evelo Biosciences’ Atopic Dermatitis Candidate Misses Primary Endpoint in Phase 2 Trialhttps://practicaldermatology.com/news/evelo-biosciences-atopic-dermatitis-candidate-misses-primary-endpoint-in-phase-2-trial/2461540/Data from first three cohorts of Evelo Biosciences’ EDP1815 Phase 2 trial show the atopic dermatitis drug candidate did not meet the primary endpoint, the company announced on Wednesday. Evelo stated that there was an unusually high placebo response rate in the first three cohorts of the st
- Meet FACE by Galdermahttps://practicaldermatology.com/news/meet-face-by-galderma/2461524/Galderma is launching FACE by Galderma, an app that simulates the results of injectable treatments in real time using digital facial assessment. The technology was unveiled at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris. FACE by Galder
- Revealed: The Genetic Basis of 13 Pigment Traits and Their Relationship with Diseaseshttps://practicaldermatology.com/news/revealed-the-genetic-basis-of-13-pigment-traits-and-their-relationship-with-diseases/2461515/Researchers have uncovered the genetic basis of 13 pigment traits and their association with diseases. Using the GCAT cohort, researchers built a comprehensive analysis strategy leading to the identification of phototype associated-diseases in a total of nearly 20,000 Ca